Status:
COMPLETED
Efficacy & Safety of SmofKabiven Emulsion for Infusion vs Hospital Compounded "All in One" for Parenteral Nutrition
Lead Sponsor:
Fresenius Kabi
Collaborating Sponsors:
Parexel
Conditions:
Parenteral Nutrition
Surgery
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The present protocol describes a randomized, patient-blinded study in which either SmofKabiven emulsion for infusion or a hospital compounded "All in one" control Total Parenteral Nutrition (TPN) regi...
Detailed Description
In addition, other variables will be assessed in this study, i.e., postsurgical new onset of nosocomial infection, CRP, free fatty acids, immunology parameters, the results of physical examination, vi...
Eligibility Criteria
Inclusion
- Patient is scheduled to undergo elective gastrointestinal surgery;
- Female or male patients, age ≥ 18 and ≤ 80 years;
- Postoperatively, patient is expected to receive 100% of the total daily energy demand via PN for at least 5 consecutive days;
- Body Mass Index (BMI) ≥ 16 kg/m2 and ≤ 30 kg /m2, and actual body weight ≥ 40 kg;
- Patient is capable to give Informed Consent, agrees to participate in the study, and signs the Informed Consent Form.
Exclusion
- Patient has received PN or parenteral amino acids in the last 10 days before randomization (exception: administration of glucose will be allowed);
- Known severe liver insufficiency in the medical history, or AST or ALT at least 3.0-times higher than the upper limit of normal range or total bilirubin at least 1.5-times higher than the upper limit of normal range;
- International Normalised Ratio (INR) at least 1.5 times higher than the upper limit of normal range;
- Uncontrolled hyperglycaemia defined as fasting blood glucose \> 180 mg/ dl (10 mmol/L);
- Severe renal impairment defined as serum creatinine value at least 1.5 times higher than the upper limit of normal range;
- Serious hyperlipidaemia (serum cholesterol and/or triglycerides and/or LDL-C level at least 1.5 times higher than the upper limit of normal range);
- Known inborn abnormality of amino acid metabolism in the medical history;
- Known acute pancreatitis in the medical history;
- Known hypothyroidism or hyperthyroidism in the medical history;
- Serum level of any of the electrolytes (sodium, potassium, magnesium, total calcium, chloride, phosphate) above the upper limit of the normal range;
- Known unstable metabolism in the medical history (e.g., metabolic acidosis);
- Known hypersensitivity to fish, egg, soybean, or peanut protein or to any of the active substances or excipients of the study drugs in the medical history;
- General contraindications to infusion therapy: acute pulmonary oedema, hyperhydration, and decompensated cardiac insufficiency /congestive heart failure;
- Unstable haemodynamic conditions (e.g., acute myocardial infarction, stroke, embolism, severe sepsis, shock);
- Known hemophagocytic syndrome;
- Patients diagnosed with an infection before the surgery;
- Drug abuse and/or chronic alcoholism;
- Psychiatric diseases, epilepsy;
- Administration of growth hormones within the previous 4 weeks before surgery, or chronic maintenance therapy with systemic glucocorticoids 4 weeks before surgery;
- Participation in a clinical study with an investigational drug or an investigational medical device within one month prior to start of study or during study;
- Patient is pregnant or lactating and intends to continue breast-feeding;
- Development of intraoperative/ postoperative conditions (assessed after surgery and before enrolment of patients):
- Intra-operative blood loss \> 1000 ml;
- Development of a condition in which PN is contraindicated;
- Intra- or postoperative urine output \< 0.5 ml/kg/h;
- Need for postoperative haemofiltration or dialysis;
- Contraindication or inability to obtain central venous catheter access;
- Intra-operative decision on limited treatment, e.g. due to diagnosis of carcinomatosis;
- Intra-operative severe complications including resuscitation, hemorrhagic and septic shock, acute single and multiple organ dysfunction including pulmonary, hepatic, and renal dysfunction prohibiting early postsurgical extubation, requiring liver-specific treatment and renal replacement therapy.
Key Trial Info
Start Date :
January 3 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 23 2020
Estimated Enrollment :
273 Patients enrolled
Trial Details
Trial ID
NCT03792100
Start Date
January 3 2019
End Date
January 23 2020
Last Update
August 2 2021
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Friendship Hospital, Capital Medical University
Beijing, China
2
The Second Hospital of Jilin University
Changchun, China
3
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
4
Thepeople's hospital of Guangxi zhuang
Nanning, China